Home » Newsletters » BioWorld Asia

BioWorld Asia

May 14, 2003

View Archived Issues

Longtime U.S. Investor Adds Perspective To GLSV Venture

MUNICH, Germany - Is this the worst bear market he's ever seen in biotechnology? (BioWorld International) Read More

QLT, Xenova Suffer Setback As Pivotal Tariquidar Trial Stopped

Molecular Zipper Helps Bind Bacteria To Human Host Cells

European Ministers Review Plan To Implement Biotech Strategy

Acambis Benefits From U.S. Consolidation Of Contracts

UK Industry Riding Out Downturn, Surviving Till Sector Turns Around

Tel Aviv University Forms Fund To Push Commercial Potential

Vivalis Licenses Stem Cell Lines To Aventis For Vaccine Production

Axaron Cutback To Focus On Stroke Reflects German Sector

Other News To Note

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...